CINECA IRIS Institutional Research Information System

OLIVERO, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.033
EU - Europa 2.988
AS - Asia 2.000
SA - Sud America 84
AF - Africa 67
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 8
Totale 10.214
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.911
CN - Cina 875
IT - Italia 643
SE - Svezia 413
DE - Germania 403
SG - Singapore 377
IE - Irlanda 363
FR - Francia 245
UA - Ucraina 175
FI - Finlandia 139
IN - India 136
GB - Regno Unito 131
KR - Corea 129
VN - Vietnam 129
CA - Canada 95
AT - Austria 85
JP - Giappone 69
ID - Indonesia 66
RU - Federazione Russa 64
PL - Polonia 58
BR - Brasile 53
ES - Italia 53
GR - Grecia 46
HK - Hong Kong 41
TW - Taiwan 38
NL - Olanda 37
AU - Australia 33
BE - Belgio 33
TR - Turchia 30
PK - Pakistan 23
CH - Svizzera 19
MX - Messico 19
RO - Romania 17
DK - Danimarca 14
UZ - Uzbekistan 13
CO - Colombia 12
EG - Egitto 11
AR - Argentina 9
IR - Iran 9
MN - Mongolia 9
PH - Filippine 9
PT - Portogallo 9
EU - Europa 8
LU - Lussemburgo 8
MY - Malesia 8
CZ - Repubblica Ceca 7
GA - Gabon 7
TH - Thailandia 7
YE - Yemen 7
ZA - Sudafrica 7
NO - Norvegia 6
PE - Perù 6
HR - Croazia 5
HU - Ungheria 5
IQ - Iraq 5
NG - Nigeria 5
SD - Sudan 5
TN - Tunisia 5
EC - Ecuador 4
IL - Israele 4
CM - Camerun 3
DZ - Algeria 3
MU - Mauritius 3
OM - Oman 3
SA - Arabia Saudita 3
BD - Bangladesh 2
BF - Burkina Faso 2
BG - Bulgaria 2
CD - Congo 2
CI - Costa d'Avorio 2
ET - Etiopia 2
GE - Georgia 2
LB - Libano 2
NP - Nepal 2
PR - Porto Rico 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
UG - Uganda 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BJ - Benin 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GH - Ghana 1
GT - Guatemala 1
HT - Haiti 1
JM - Giamaica 1
LT - Lituania 1
MA - Marocco 1
MK - Macedonia 1
ML - Mali 1
MW - Malawi 1
NZ - Nuova Zelanda 1
RS - Serbia 1
RW - Ruanda 1
SC - Seychelles 1
ZM - Zambia 1
Totale 10.214
Salva come PNG Salva come JPEG
Città #
Chandler 663
Beijing 442
Ann Arbor 429
Santa Clara 394
Dublin 362
Singapore 313
Fairfield 196
Ashburn 174
Houston 167
Nyköping 149
Jacksonville 137
Dearborn 132
Wilmington 129
Torino 128
Medford 126
Villeurbanne 126
Redwood City 121
Princeton 112
Woodbridge 112
Columbus 95
Vienna 78
Seattle 73
Dong Ket 66
Turin 64
Guangzhou 58
Cambridge 57
Fremont 57
Pisa 50
Warsaw 49
Jakarta 48
Ottawa 46
Shanghai 44
Boston 40
Rome 34
Boardman 28
Nanjing 28
New York 27
Taipei 26
Toronto 26
Milan 25
Tokyo 24
Stockholm 23
Chengdu 22
West Jordan 22
Wuhan 22
Kunming 21
Brussels 20
Hanoi 20
Helsinki 20
San Diego 20
Hangzhou 18
Paris 18
Delhi 17
Pune 17
Bengaluru 16
Seoul 16
Los Angeles 15
Madrid 15
Washington 15
Duncan 14
Wokingham 14
Munich 13
San Mateo 13
Central District 12
Hefei 12
Ho Chi Minh City 12
Athens 11
Falls Church 11
Gurgaon 11
Hyderabad 11
London 11
Norwalk 11
Ankara 9
Bucharest 9
Düsseldorf 9
Lahore 9
Nuremberg 9
Bologna 8
Council Bluffs 8
Naples 8
Verona 8
Amsterdam 7
Atlanta 7
Barcelona 7
Belo Horizonte 7
Chicago 7
Chongqing 7
Hanover 7
Hebei 7
Hong Kong 7
Kumar 7
Libreville 7
Nanchang 7
Napoli 7
Pacifica 7
Phoenix 7
Sanaa 7
Shenzhen 7
Sydney 7
Tashkent 7
Totale 6.158
Salva come PNG Salva come JPEG
Nome #
Hepatitis delta virus diagnosis. 748
Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays. 438
Outcome of chronic delta hepatitis in Italy: a long-term cohort study. 370
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 368
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 327
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 272
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 174
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 165
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 152
Multiple courses of G-CSF in patients with decompensated cirrosi: consistent mobilization of immature cells ex pressing hepatocyte markers and exploratory clinical evaluation. 144
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 131
Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma 124
Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease 122
Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 122
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 121
Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations 120
Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma 120
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma 118
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 115
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 114
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 112
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 110
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D 107
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B 106
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 106
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology 106
Incidence of Type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: results of a controlled follow-up study. 104
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 104
Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis 103
Inactive hepatitis B virus carriers: a favourable clinical condition 101
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study 99
Diagnostic accuracy of soluble sCD163 for the detection of severe fibrosis in patients with Non-Alcoholic Fatty Liver Disease 99
Azione antiproliferativa e modificazioni del citoscheletro indotte da azossicianuri in fibroblasti 97
AGGIORNAMENTI SULLA TERAPIA DELL'EPATITE B E DELTA 96
Increased Pre-Hepatic Insulin Levels Are Directly Related to Nash, Fibrogenesis and Fibrosis in Non Diabetic NAFLD Patients but Not in Type 2 Diabetes 96
Role of serum hepatitis B core-related antigen in chronic hepatitis B infection 94
Some biological effects of calvatic acid and its analog on isolated hepatocytes. 93
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine 93
Prevalence of hepatitis C virus/hepatitis G virus co-infection in Turin: updated data ten years later. 93
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in patients with chronic hepatitis D 92
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection 92
Epatocarcinoma: biomarcatori nella prevenzione, diagnosi e cura 91
Effetto antimicrotubulare della geiparvarina, del dietilstilbestrolo e del loro prodotto di coniugazione 90
Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease 90
DROPLET DIGITAL PCR APPLICATION FOR HEPATITIS DELTA VIREMIA QUANTIFICATION 86
Risk of developing hepatocellular carcinoma in patients with cirrhosis of viral etiology evaluated by the combination of alphafetoprotein, protein induced by vitamin K absence or antagonist-II and glypican-3 85
Aldehyde-induced modifications of the microtubular system in 3T3 fibroblasts. 83
Microarrays analysis for predicting treatment response in patients with chronic hepatitis C: preliminary data 83
Cytoskeletal modifications induced by 4-hydroxynonenal 82
Application of serum cytokeratin-19 fragments (CYFRA 21-1) in predicting the prognosis of patients with hepatocellular carcinoma 81
Gene expression profiles for predicting treatment response in patients with chronic hepatitis C: preliminary analysis 79
A NOVEL APPROACH FOR HEPATITIS DELTA VIRUS VIREMIA QUANTIFICATION BY DROPLET DIGITAL PCR ASSAY 79
HBV: GLI "END-POINTS" DELLA TERAPIA CON I NUCS + UPDATE 2016 SU NUOVE STRATEGIE TERAPEUTICHE DELL'INFEZIONE CRONICA HBV 78
Antimicrotubular effect of calvatic acid and of some related compounds 77
Hepatitis B-core related antigen levels during nucleos(t)ide analogues or pegylated-interferon treatment in patients chronically infected with HBV genotype-D 77
Risk of hepatocellular carcinoma development in patients with cirrhosis of viral etiology assessed by protein induced by vitamin k absence or agonist II 77
Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease 77
Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response? 76
Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification 75
Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with non-alcoholic fatty liver disease 74
Epidemiology and clinical course of hepatitis delta virus infection over 15 years in a liver center in Northern Italy 74
4-hydroxynonenal interacts with tubulin by reacting with its functional -SH groups. 73
The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease 73
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 72
Liver transplantation for hepatitis B with delta coinfection: a single center experience 72
Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P 71
The influence of calvatic acid and some of its analogues on colchicine-binding activity of rat liver tubulin. 70
HNE antiproliferative effect can be related to an interaction with the cytoskeleton 70
Impact of IL28B genotype on response rates in hepatitis C virus cirrhotic patients treated with new DAA regimens: experience of a single center 70
Chronic hepatitis B treatmen: current perspectives on Telbivudine 69
Quantification of serum HDV RNA by ddPCR 69
Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment 65
Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience 65
Modificazioni del citoscheletro indotte dal 4-idrossinonenale 64
CROSS-SECTIONAL AND LONGITUDINAL EVALUATION OF ALPHA-FETOPROTEIN (AFP) AND PROTEIN INDUCED BY VITAMIN K ABSENCE OR ANTAGONIST II (PIVKA-II) IN PATIENTS WITH CIRRHOSIS OF VIRAL ETIOLOGY UNDER SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA (HCC) 64
Kinetics of HDV-RNA and hepatitis B surface antigen in chronic delta hepatitis under pegylated interferon and/or nucleoside analogs therapy 63
HLA-B, DRB1 alleles in Italian patients with chronic hepatitis C and responsiveness to interferon + ribavirin therapy 61
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection 61
Risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis of viral etiology evaluated by the association of alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II) and glypican-3 (GPC-3) 61
The influence of calvatic acid and some of its analogues on colchicine-binding activity of tubulin from AH-130 Yoshida ascites hepatoma 57
Interazione fra geiparvarina, dietilstilbestrolo e microtubuli 56
HEPATITIS B CORE-RELATED ANTIGEN LEVELS DURING NUCLEOS(T)IDE ANALOGUES OR PEGYLATED-INTERFERON TREATMENT IN PATIENTS WITH CHRONIC HBV-GENOTYPE D INFECTION 54
Effect of calvatic acid and its analogs on ornithine decarboxylase activity in tumour cells. 53
Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease 52
Interplay between metabolic derangement, biomarkers of collagen remodelling and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 52
Hepatitis b virus reactivation upon immunosuppression: Is there a role for hepatitis b core-related antigen in patients with immune-escape mutants? a case report 52
Interaction of C-9 aldehydes with microtubular protein in vitro and in cultured cells in the presence of taxol. 50
Epatocarcinoma: biomarcatori nella prevenzione, diagnosi e cura 50
Phenylazoxycyanide damages microtubular protein more than its reference antibiotic, calvatic acid. 49
Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy. 49
Reply to: “Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition” 49
Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development 49
Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study 48
Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells 47
Interplay between metabolic derangement, hepatic fibrogenesis and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 47
Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma 45
HCV and TTV Co-infection in Turin, Italy. 45
Insulin secretion is an independent predictor of hepatic ballooning in non-diabetic fatty liver disease. 44
Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis 43
Serum hepatitis B core-related antigen for the prediction of hepatocellular carcinoma development 43
Totale 10.329
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.881
article - articoli 0
book - libri 0
conference - conferenze 10.108
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.989
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020645 0 0 0 0 0 0 129 81 118 179 74 64
2020/20211.124 89 128 64 59 96 80 117 53 112 87 73 166
2021/20221.634 52 50 67 113 105 90 142 152 92 162 364 245
2022/20231.960 187 171 66 202 172 464 159 121 197 54 118 49
2023/2024986 128 136 82 71 60 110 45 81 6 60 90 117
2024/20251.286 68 172 107 204 570 164 1 0 0 0 0 0
Totale 10.582